2018
Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study.
Tabakin A, Sadimin E, Tereshchenko I, Kareddula A, Stein M, Mayer T, Hirshfield K, Kim I, Tischfield J, DiPaola R, Singer E. Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study. Journal Of Genitourinary Disorders 2018, 2 PMID: 30714046, PMCID: PMC6358174.Peer-Reviewed Original ResearchMonths of ADTProstate cancerProstate-specific antigen (PSA) recurrenceSpecific antigen recurrenceAndrogen deprivation therapyAdditional larger studiesProstate cancer patientsLymph node tissueCHD1 deletionDeprivation therapySerum PSAAndrogen deprivationClinical outcomesCancer patientsImmunohistochemical stainsTissue microarrayNode tissueERG fusionLarger studyIndependent correlationTumor suppressor genePilot studyStrong associationPatientsProstatectomy
2016
Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer
Parihar J, Kim I. Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer. 2016, 533-540. DOI: 10.1016/b978-0-12-800077-9.00057-8.Peer-Reviewed Original ResearchCastrate-resistant prostate cancerProstate cancerHormonal manipulationHormone-sensitive prostate cancerSecond-line hormonal manipulationsSecond-line hormonal therapySecond-line treatment optionAssociated response ratesInitial systemic therapySecondary hormonal manipulationsSecond-generation antiandrogensFirst-generation antiandrogensAntiandrogen withdrawalARN-509Hormonal therapyMainstay treatmentAbiraterone acetateAndrogen suppressionSystemic therapyAndrogen deprivationSuch patientsTreatment optionsTherapeutic responseDisease progressionResponse rate
2014
PD34-03 RADICAL PROSTATECTOMY WITH ADJUVANT RADIOTHERAPY VERSUS ANDROGEN DEPRIVATION THERAPY PLUS RADIOTHERAPY FOR ADVANCED, NON-DISTANT METASTATIC PROSTATE CANCER
Jang T, Patel N, Shen S, DiPaola R, Moore D, Kim I, Lu-Yao G. PD34-03 RADICAL PROSTATECTOMY WITH ADJUVANT RADIOTHERAPY VERSUS ANDROGEN DEPRIVATION THERAPY PLUS RADIOTHERAPY FOR ADVANCED, NON-DISTANT METASTATIC PROSTATE CANCER. Journal Of Urology 2014, 191: e896-e897. DOI: 10.1016/j.juro.2014.02.2428.Peer-Reviewed Original Research
2013
Clinical Significance of Wnt/β-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer
Jung S, Oh S, Lee G, Chung J, Min K, Yoon J, Kim W, Ryu D, Kim I, Kang D. Clinical Significance of Wnt/β-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer. The World Journal Of Men's Health 2013, 31: 36-46. PMID: 23658864, PMCID: PMC3640151, DOI: 10.5534/wjmh.2013.31.1.36.Peer-Reviewed Original ResearchWnt/β-catenin pathwayMatrix metalloproteinase-7Hormone-naïve prostate cancerΒ-catenin pathwayMMP-7 expressionAndrogen receptorProstate cancerPSA progressionHormone therapyΒ-cateninSerum prostate-specific antigen levelProstate-specific antigen levelPrimary androgen deprivationPrimary hormone therapyAndrogen receptor expressionKaplan-Meier curvesProstate cancer patientsShorter response durationHigh Gleason gradeMMP-7 proteinWnt/β-catenin signalingΒ-catenin signalingAndrogen deprivationClinicopathological factorsAdvanced cancer